Feedback Share Discussion Threads

[ducatiman] 10/12/2018 13:56

Cheers Tim. A reassuring post. Did you ask him about the Siemens bundling?

[gymratt] 10/12/2018 13:27

Thank you for your efforts, Timmy. The above bullet points reinforces the strategy of a long term hold for me until the company has grown to its full potential.
As far as I'm concerned, I'm happy with the decent position I've built up over the last few months and now it's a matter of patience whilst the story unfolds.
Hopefully FDBK will gain FDA approval within the next year and crack the US market to add to Europe and Asia sales.
Back to lurking...
GLA

[ged5] 10/12/2018 11:30

Anything that saves having ones neck slashed is good, very very good.

Yes I've been focusing on the conclusions in the research notes and it appears that TexRAD is a useful piece of software in several areas, hence one of the questions I posted for Tim to ask in his meeting with Alistair Riddell.

I recall that AR did allude to other areas of use for TexRAD in his interview.

[lr2] 10/12/2018 11:01

I'm glad you thought that link was interesting Ged. All very promising.

[ged5] 10/12/2018 10:19

Well another bullish interview but still no interest. Everyone buying Christmas presents?

[ged5] 10/12/2018 09:58

Thanks LR2

So TexRAD has been used in this research with high accuracy.

PATIENT IMPACT
If these results are validated in larger studies with independent samples,
they could form the basis of clinical assistant tools enabling non-invasive
diagnostic evaluation beyond what is currently done in clinical practice.
This could lead to more accurate diagnosis, a reduction in unnecessary
neck dissections or extent of neck dissections with a concomitant reduction
in associated morbidity, and ultimately more precise, personalized therapy.

CONCLUSION
Radiomic analysis with machine learning can be used for identification and
characterization of metastatic HNSCC nodes with a high accuracy.
If validated in larger samples using different techniques, the results of this
pilot study have the potential to form the basis for clinical assistant
diagnostic tools that will improve non-invasive pre-treatment diagnostic evaluation of HNSCC and associated lymphadenopathy.

TRANSLATION ACROSS THE RCN
We are already in the process of expanding this project from a single site
to a multi-site study that includes the Jewish General Hospital and McGill
University Health Centre. Furthermore, the approaches developed and
applied are generalizable and can be applied to other diseases.

[lr2] 09/12/2018 17:23

Not seen this research before. Not sure how old it is. Interesting anyway.

[ducatiman] 08/12/2018 21:10

Good to hear you are ok LR2. Hope your Sis gets better soon, with your help.

[lr2] 08/12/2018 13:56

Hi Duc, yes I'm fine but my sister is not so good at present so I'm spending more time with her and less time chatting on here. Many thanks to Ged for posting the video, it was a good listen. I'm pretty confident that things will pick up for Feedback in due course. Patience is all that's needed.

[ducatiman] 08/12/2018 13:25

Cheers Ged. Posts on this thread are like London buses, lol.
You ok LR2?

[ged5] 08/12/2018 13:24

From the interview:

Sound financial position
Growing commercial progress
Affirmation of the quality of our products

Theme for the year:
Continue for upward growth
Interesting strategic business developments

Maybe we'll get some volume this week after snoozing this past fortnight!

[ged5] 08/12/2018 12:53

Redone your link Tim to make it easier to access.

[flashheart] 08/12/2018 11:49

Thanks to you both. An interesting listen.

[ged5] 08/12/2018 11:19

Thanks Tim.

There you go ducatiman. ADVFN don't allow links to pro active.

[tim000] 08/12/2018 10:38

Herald seems to be a good fund manager. Their Interim Report for 2018 H1 is an interesting read.

hxxps://www.heralduk.com/wp-content/uploads/2018/08/HWF-Interim-2018.pdf

[ducatiman] 08/12/2018 09:40

www.heralduk.com

[ducatiman] 08/12/2018 09:32

Thanks tim, tried to copy link but failed. I know LR2 can do it so hopefully he will copy when he sees post. I wasn't expecting FDA approval before May but hopefully some time next year. He names the inst investor as Herald. I will have a look at them. He also expects more inst interest as they grow. All very positive again.
Look forward to your report tim.

[tim000] 08/12/2018 08:30

Alastair has given another interview on proactive investors.

I'm meeting him Monday morning and will report back afterward. In the interview he says that he can't give a timeframe for FDA approval, but very likely not before the next FY. I reread the AR release prior to our meeting and I agree that there is lots of potential here, in particular getting Texrad involved in patient prognosis. That would be a game changer. At the moment, it's still all potential though.

[sonie01] 04/12/2018 08:24

Are the brokers manipulating this?

[ducatiman] 04/12/2018 08:22

I thought we had turned the corner after the very positive results statement. Obviously not :-(

[ducatiman] 30/11/2018 19:12

Good grief tim, first name terms already, lol. Good luck tim and thank you. Impressions will probably mean more than the answers. I repeat that it is very encouraging to see that fdbk are prepared to engage with PIs in this manner. Look for ward to your feedback!

[tim000] 30/11/2018 18:18

I'll probably email them to Alastair in advance anyway.

[ducatiman] 30/11/2018 16:43

We know fdbk read this thread so I would think they will be well prepared for tim's questions.

[petekand] 30/11/2018 15:38

Strange that someone paid full offer for only 1000 shares. Any idea on the limits? I don't want these to run away whilst I'm thinking of averaging down!